Advancing Cell & Gene Therapies: Overcoming Challenges, Embracing Innovation & Shaping 2025
Cell & Gene
The most valuable resource for professionals who make their living in the cell & gene therapies industry.
TRENDING CONTENT - Catch Up
Explore the immense potential of gamma delta T cells, as well as the challenges in sourcing and scaling up sufficient volumes to treat enough patients.
Examine the evolution of CAR T-cell therapy, its expanding role in earlier cancer treatment, challenges in applying it to solid tumors, and the future potential of generating CAR T-cells directly within patients. We highlight key scientific advancements, ongoing research, and the importance of learning from failures to drive innovation in stem cell therapy.
Discover the critical role of leukapheresis in gene-modified T-cell therapy manufacturing. Learn how factors like anticoagulation, extracorporeal volume, and patient preparation impact collection efficiency. Explore best practices for optimizing donor eligibility, ensuring regulatory compliance, and standardizing processes to enhance the safety, consistency, and effectiveness of cell therapies.
Delve into the challenges of host cell DNA (hcDNA) impurities in recombinant AAV (rAAV) gene therapy. Nic Preyat at of UCB Pharma discusses potential risks, current limitations in purification, and the evolving regulatory landscape. Learn how process development strategies, from upstream cell line selection to downstream purification, can help mitigate hcDNA while maintaining product yield and safety.
This report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
US Pharmacopeia is developing reference standards to improve the quality of AAV gene therapy production. By standardizing raw materials like plasmid DNA and endonucleases, USP aims to enhance testing consistency, reduce impurities, and lower manufacturing costs, supporting the industry's growth.
“Understanding the delivery of genetic material to the heart using our delivery systems, making sure that we’re getting the right expression at the right doses … in a rare population is absolutely the right thing to do before we move over to more prevalent forms of heart disease.” Tenaya Therapeutics CEO, Faraz Ali
CELL & GENE LIVE! - Register Now
Emerging Manufacturing Technologies For Cell Therapies
Thursday, March 13, 2025 11:00 AM Eastern Standard Time 1 hour
How can 3D cultures, organoids, & automation revolutionize cell therapy? Cell & Gene Live host, Erin Harris, welcomes experts Rohit Ingale of Arcellx & David O'Donnell from Vor Bio for an exploration of novel techniques to accelerate the development and production of transformative cell therapies! Don't miss this deep dive into the future of manufacturing! Registration is free thanks to the support of CPC and MaxCyte.